ArticleInternational journal of environmental research and public health2022
Cost-Benefit Analysis of Interventions to Mitigate the Monkeypox Virus.
Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- The Role of Pharmacists in Tackling Mpox: Challenges and Future Prospects: A Narrative Review.Health science reports · 2026Article
- COVID-19 and MPXV: Twindemic Response and Dual Infections in Individuals in a US Metro.Epidemiologia (Basel, Switzerland) · 2025Article
- A Compartmental Mathematical Model to Assess the Impact of Vaccination, Isolation, and Key Epidemiological Parameters on Mpox Control.Medical sciences (Basel, Switzerland) · 2025Article
- The global patent landscape of emerging infectious disease monkeypox.BMC infectious diseases · 2024Article
- Role of vaccination in patients with human monkeypox virus and its cardiovascular manifestations.Annals of medicine and surgery (2012) · 2024Review
- Characterizing Indicators of Engagement in HIV-Associated Healthcare and Clinical Outcomes among People with HIV and Mpox in Washington, DC: A Nested Case-Control Study of the DC Cohort.Pathogens (Basel, Switzerland) · 2024Article
- Willingness to accept monkeypox vaccine and its correlates among men who have sex with men in Southern China: a web-based online cross-sectional study.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When a viral outbreak occurs, governments are obligated to protect their citizens from the diverse adverse effects of the disease. Health policymakers often have several interventions to consider based on the health of the population, as well as the cascading social and economic consequences of the possible mitigation strategies. The current outbreak of the monkeypox virus has elicited debate on the best mitigation strategy, especially given that most world economies are still recovering from the harsh economic effects of the COVID-19 pandemic. This paper sought to analyze the costs and benefits of three possible strategies and determine which option has the best health outcomes and positive economic effects. A case study of Jeddah was performed, whereby a model was simulated to determine the number of infections over 28 days based on one case of the monkeypox virus. Findings reveal that the vaccination provides the best intervention, as it effectively reduces the transmission rate and prevents loss of lives in the city. From the model, only three people were infected over the research period, while no deaths were reported. Although vaccination incurs a huge direct cost at the beginning, in the long run, it saves the economy from the disease's financial burden in terms of productivity loss from work absenteeism and premature deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.